Computational study on the affinity of potential drugs to SARS-CoV-2 main protease.

J Phys Condens Matter

Departamento de Química Física y Química Inorgánica, Universidad de Valladolid, 47011 Valladolid, Spain.

Published: May 2022

Herein, we report a computational investigation of the binding affinity of dexamethasone, betamethasone, chloroquine and hydroxychloroquine to SARS-CoV-2 main protease using molecular and quantum mechanics as well as molecular docking methodologies. We aim to provide information on the anti-COVID-19 mechanism of the abovementioned potential drugs against SARS-CoV-2 coronavirus. Hence, the 6w63 structure of the SARS-CoV-2 main protease was selected as potential target site for the docking analysis. The study includes an initial conformational analysis of dexamethasone, betamethasone, chloroquine and hydroxychloroquine. For the most stable conformers, a spectroscopic analysis has been carried out. In addition, global and local reactivity indexes have been calculated to predict the chemical reactivity of these molecules. The molecular docking results indicate that dexamethasone and betamethasone have a higher affinity than chloroquine and hydroxychloroquine for their theoretical 6w63 target. Additionally, dexamethasone and betamethasone show a hydrogen bond with the His41 residue of the 6w63 protein, while the interaction between chloroquine and hydroxychloroquine with this amino acid is weak. Thus, we confirm the importance of His41 amino acid as a target to inhibit the SARS-CoV-2 Mpro activity.

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-648X/ac6c6cDOI Listing

Publication Analysis

Top Keywords

dexamethasone betamethasone
16
chloroquine hydroxychloroquine
16
sars-cov-2 main
12
main protease
12
potential drugs
8
drugs sars-cov-2
8
betamethasone chloroquine
8
molecular docking
8
amino acid
8
sars-cov-2
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!